Phase 1Recruiting
A Dose Randomization Study of Bulumtatug Fuvedotin in TNBC Patients Previously Treated With ADCs
Sponsored by Mabwell (Shanghai) Bioscience Co., Ltd.
About this study
The goal of this clinical trial is to investigate if treatment with bulumtatug fuvedotin is effective in triple-negative breast cancer patients who have previously received treatment with an antibody-drug conjugates.
Enrolling at this location
UChicago Medicine Comprehensive Cancer Center
Chicago, Illinois
I'm interestedThis study also enrolls at 5 other locations. See all.
Completing a questionnaire on Clinably does not enroll you in a clinical trial or confirm your eligibility. Only the research team can determine whether you qualify to participate. These results are based on the information you provide and are intended to help you start a conversation with the research team.
Trial data sourced from ClinicalTrials.gov.